But studies weren’t designed to prove proton pump inhibitors are responsible for the increase
TUESDAY, Oct. 27, 2015 (HealthDay News) — Proton pump inhibitors (PPIs) appear to be linked with increased risk of chronic kidney disease, two new studies suggest. Findings from the studies are scheduled to be presented next week at the American Society of Nephrology’s Kidney Week 2015, held from Nov. 3 to 8 in San Diego.
For one study, Pradeep Arora, M.D., a nephrologist and associate professor at the SUNY Buffalo School of Medicine and Biomedical Science in New York, and colleagues included 24,149 patients who developed chronic kidney disease between 2001 and 2008. One out of four of the kidney patients had been previously treated using a PPI. Patients taking a PPI also had an increased risk of dying prematurely, the researchers found.
In the second study, researchers were led by Benjamin Lazarus, M.B.B.S., from the Royal Brisbane and Women’s Hospital in Australia, and Johns Hopkins University in Baltimore. The team followed 10,482 adults with normal kidney function from 1996 to 2011. They found that PPI users were up to 50 percent more likely to develop chronic kidney disease than non-PPI users, even after adjusting for differences between the two groups.
“In both studies, people who used a different class of medications to suppress stomach acid, known as H2-blockers, did not have a higher risk of developing kidney disease,” Lazarus said in an American Society of Nephrology news release. “If we know the potential adverse effects of PPI medications we can design better interventions to reduce overuse.”
Copyright © 2015 HealthDay. All rights reserved.